We’re excited to share that we’ve reached 𝟏𝟓,𝟎𝟎𝟎 𝐟𝐨𝐥𝐥𝐨𝐰𝐞𝐫𝐬 on LinkedIn! A huge thank you to our clients and candidates for trusting us to support your journeys. Your partnership means everything, and we’re proud to be part of the incredible work happening across the industry! #Milestone #Growth #Teamwork #Innovation #Career
Global Life Science Hub
Pharmaceutical Manufacturing
Multidiscipline headhunting firm providing comprehensive consultancy services to the Pharma and Medical Device industry.
About us
With over 20 years of experience across our senior leadership team, The Global Life Science Hub provides functional services and consulting with a solid mission to accelerate, strengthen and enhance global clinical trials. Financially backed by a global specialist head-hunting firm. We are primed to continue the growth and development in the Clinical, Regulatory Quality, Manufacturing and Biometrics sectors to effectively expand our functional services globally. The Global Life Science Hub strives to ensure that all of our clinical research clients can meet their end-point goals by providing a better alternative to recruitment agencies, CROs, CDMOs and other 3rd party vendors.
- Website
-
http://www.glshub.com
External link for Global Life Science Hub
- Industry
- Pharmaceutical Manufacturing
- Company size
- 2-10 employees
- Headquarters
- London
- Type
- Public Company
- Founded
- 2021
- Specialties
- recruitment, pharmaceuticals, life science, hiring, clinical research, biometrics, project management, CRO, Pharma, biotech, clinical trial management, Manufacturing, Production, Regulatory, Quality, Quality Assurance, Quality Control, manufacturing, and CDMO
Locations
-
Primary
London, GB
-
901 4th St N
St Petersburg, Florida 33701, US
Employees at Global Life Science Hub
-
Christopher Antoniou
CEO & Founder of Global Life Science Hub - Pharmaceutical Manufacturing Expert
-
Alexander Antoniou
CEO & Founder of AL Solutions - Headhunting Senior Executives, Life Sciences - USA & EMEA
-
Zeliha Y.
Şu okulda öğrenci: Uludağ Üniversitesi
-
Kayleigh Stephens
Accounts & Operations Manager at AL Solutions
Updates
-
Halozyme, Inc. 𝐡𝐚𝐬 𝐦𝐚𝐝𝐞 𝐚 𝐛𝐨𝐥𝐝 $𝟐.𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐨𝐟𝐟𝐞𝐫 𝐭𝐨 𝐚𝐜𝐪𝐮𝐢𝐫𝐞 Evotec, aiming to diversify beyond its Enhanze drug delivery technology, used in treatments by Johnson & Johnson and Roche. The bid comes at a 27.5% premium following Evotec's share price drop amid interest from private equity firm Triton Partners. This acquisition could position Halozyme for sustained growth as it plans for life after Enhanze’s key patents expire in 2027. Evotec’s drug discovery expertise could open new doors for Halozyme in the biopharma space. Watch this space! https://lnkd.in/eKZGsvum #Biopharma #Mergers #Innovation #DrugDelivery
-
BioNTech SE is taking a major step to lead the 𝐢𝐦𝐦𝐮𝐧𝐨-𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 space, investing $𝟖𝟎𝟎 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 upfront to acquire its Chinese partner Biotheus Inc.. This deal secures BioNTech full rights to BNT327 (PM8002), a promising PD-L1xVEGF-A bispecific drug with the potential to redefine cancer treatment standards. With checkpoint inhibitors evolving, BioNTech's expanded stake highlights its commitment to advancing therapies that could challenge current cancer blockbusters. https://lnkd.in/eGFm93yA #BioNTech #CancerResearch #ImmunoOncology #BiotechNews
BioNTech pays $800M to take control of potential Keytruda killer
fiercebiotech.com
-
AstraZeneca 𝗘𝘅𝗽𝗮𝗻𝗱𝘀 𝗨.𝗦. 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗯𝘆 $𝟮 𝗕𝗶𝗹𝗹𝗶𝗼𝗻! With confidence in U.S. economic growth, AstraZeneca is adding $𝟮 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 to its investment in American manufacturing and R&D, bringing the total to$𝟯.𝟱 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 𝟮𝟬𝟮𝟲. This move will create 1,000+ jobs and support new facilities, including a next-gen biologics plant in Maryland, expanded cell therapy capacity on both coasts and speciality manufacturing in Texas. The investment will also advance AstraZeneca’s R&D efforts with a centre in Cambridge, MA. https://lnkd.in/gwKbCfsY #AstraZeneca #LifeSciences #Manufacturing #Biologics #CellTherapy #ResearchAndDevelopment
With high hopes for the economy, AstraZeneca adds $2B to US investment in manufacturing, R&D
fiercepharma.com
-
Daiichi Sankyo US has entered a $𝟯𝟬𝟬𝗠 licensing deal with Korea's ALTEOGEN Inc. to develop a subcutaneous version of their blockbuster antibody-drug conjugate, Enhertu . This game-changing collaboration could bring a new formulation of Enhertu to market, with Alteogen set to receive $20M upfront, plus additional milestones and royalties tied to sales. With Enhertu having pulled in $2.5 billion in global sales in 2023, this partnership is poised to further boost its impact in the oncology space. https://lnkd.in/eds_V3vi #Biopharma #LicensingDeal #Enhertu #Innovation #Partnership
Daiichi Sankyo links up with Korea's Alteogen on subcutaneous Enhertu in $300M licensing deal
fiercepharma.com
-
Global Life Science Hub reposted this
Global Life Science Hub is actively recruiting 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲𝘀 (𝗟𝗲𝘃𝗲𝗹𝘀 𝗜, 𝗜𝗜, 𝗮𝗻𝗱 𝗜𝗜𝗜), 𝗔𝘀𝗲𝗽𝘁𝗶𝗰 𝗦𝘂𝗽𝗲𝗿𝘃𝗶𝘀𝗼𝗿𝘀, 𝗮𝗻𝗱 𝗗𝗼𝘄𝗻𝘀𝘁𝗿𝗲𝗮𝗺 𝗦𝘂𝗽𝗲𝗿𝘃𝗶𝘀𝗼𝗿𝘀 for a rapidly expanding pharmaceutical leader in 𝗖𝗵𝗶𝗰𝗮𝗴𝗼, 𝗨𝗦𝗔. As this innovative company scales up to 𝟮,𝟬𝟬𝟬-𝗹𝗶𝘁𝗿𝗲 𝗯𝗶𝗼𝗿𝗲𝗮𝗰𝘁𝗼𝗿𝘀 and 𝘁𝗿𝗶𝗽𝗹𝗲𝘀 𝘁𝗵𝗲𝗶𝗿 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻, they are experiencing exceptional growth backed by a robust and diverse pipeline, ensuring stability and long-term potential for their team. If you'd like to join a thriving environment with huge opportunities for career growth, then reach out directly to me to discuss where you could fit into this team. Alternatively, we have a huge number of open mandates; feel free to have a look! https://lnkd.in/ex8zwqYx #BiopharmaJobs #ManufacturingCareers #PharmaceuticalIndustry #Hiring
77 Jobs in Worldwide (10 new)
linkedin.com
-
Novo Nordisk has struck a $𝟐𝟖𝟓𝐌 𝐝𝐞𝐚𝐥 with Ascendis Pharma to develop a once-monthly GLP-1 receptor agonist for #obesity and #diabetes, leveraging Acendis’ TransCon tech to improve dosing convenience. https://lnkd.in/ezjTTu8X #PharmaNews #NovoNordisk #AscendisPharma #GLP1 #Biotech
Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist
fiercebiotech.com
-
𝐃𝐨𝐰𝐧𝐬𝐭𝐫𝐞𝐚𝐦 𝐏𝐫𝐨𝐜𝐞𝐬𝐬𝐢𝐧𝐠 𝐒𝐮𝐩𝐞𝐫𝐯𝐢𝐬𝐨𝐫𝐬 | 𝐂𝐡𝐢𝐜𝐚𝐠𝐨 Global Life Science Hub is urgently seeking 2x Downstream Processing Supervisors for a rapidly expanding biotech to support their 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 team in 𝐂𝐡𝐢𝐜𝐚𝐠𝐨. If you, or anyone you know, could be a good fit, then please reach out! #BiotechJobs #Biomanufacturing #BiopharmaCareers #DownstreamProcessing #ChicagoJobs
-
Global Life Science Hub reposted this
At Global Life Science Hub, we're entering a new growth phase and are seeking several passionate consultants/senior consultants to join our team. If you're tired of complicated commission structures, restrictive processes, or barriers around cross-selling and market expansion, let's have a conversation. Over the last 3 years, we’ve built a solid foundation and are now poised for major growth. You’ll start with a warm desk and access to over 50 live mandates across the US and EU, with full autonomy to build your own desk in any market with no limitations. For more details, get in touch with myself or Christopher Antoniou. https://lnkd.in/efFAhpwc #hiring #recruitment #lifesciences #careeropportunity
-
Global Life Science Hub has several exciting openings with a fast-growing biotech company in 𝗖𝗵𝗶𝗰𝗮𝗴𝗼! This company has recently secured two FDA approvals and boasts a strong pipeline of advanced therapies. We’re looking for talented individuals to join their downstream manufacturing team in Chicago. Apply using the links below! 𝗗𝗼𝘄𝗻𝘀𝘁𝗿𝗲𝗮𝗺 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲𝘀 𝗜, 𝗜𝗜 & 𝗜𝗜𝗜 >Apply via https://lnkd.in/gUPByqbu 𝗗𝗼𝘄𝗻𝘀𝘁𝗿𝗲𝗮𝗺 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗦𝘂𝗽𝗲𝗿𝘃𝗶𝘀𝗼𝗿 >Apply via https://lnkd.in/gdBBc3hq #hiring #biotech #manufacturing #lifesciences #careers